Drug infusion systems are used across pharmacological therapies to administer various drugs including antibiotics, insulin, chemotherapy drugs, painkillers, intravenously or through non-oral routes, like epidural routes and intramuscular injections in a controlled manner.
The Global drug infusion system market is expected to offer lucrative growth in the coming years owing to the increasing prevalence of chronic diseases and rising geriatric population across the globe.
The rise in chronic diseases has led to high demand for better medicines and facilities. For instance, as per the latest estimates by the IDF Diabetes Atlas Ninth edition 2019, around 463 million people aged between 20-79 years were living with diabetes in 2019; the number is estimated to reach 700 million by 2045. Moreover, the prevalence of genetic diseases and cancer has witnessed an upsurge in recent years. For the advanced and continued care of the patients, the drug infusion systems are being extensively used in hospitals and critical care centers.
On the other side, the high cost of the drug infusion system and stringent government regulations are expected to restrain the market's growth during the forecast period.
The Global Drug infusion systems market is segmented on the basis of product type, application, and region. Based on the product type, the market is divided into large volume infusion systems, patient-controlled analgesia, elastomeric infusion pumps, insulin infusion pumps, syringe infusion systems, implantable infusion systems, ambulatory infusion systems, and enteral infusion systems. On the basis of application, the market is divided into oncology/chemotherapy, diabetes, analgesia, nutrition, haematology, pediatrics, and other applications.
Based on the region, the market is studied across North America, Asia-Pacific, Europe, and LAMEA. North America held the largest share of the market in 2019, followed by Europe and Asia Pacific. However, the Asia Pacific is projected to have the highest growth rate during the forecast period.
The key players operating in the market include Acromed AG, B. Braun Melsungen AG, Baxter International Inc., Becton, Dickinson and Company, Caesarea Medical Electronics Ltd., Debiotech S.A., Flowonix Medical Inc., Fresenius SE & Co. KGaA, Halyard Health, Inc., ICU Medical Inc., IRADIMED CORPORATION, Insulet Corporation, Medtronic, MOOG, Inc., Smiths Group plc, Tandem Diabetes Care, Inc., Terumo Corporation and Zyno Medical, LLC among others.